Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The combination with Custopharm enhances Hikma’s R&D capabilities and pipeline and expands Hikma’s differentiated US portfolio to close to 130 commercialised injectable medicines – a more than fivefold increase over the last decade, including Acetaminophen injection.
Lead Product(s): Paracetamol
Therapeutic Area: Neurology Product Name: Acetaminophen-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hikma Pharmaceuticals
Deal Size: $425.0 million Upfront Cash: $375.0 million
Deal Type: Acquisition April 21, 2022
Details:
The combination with Custopharm enhances Hikma’s R&D capabilities and pipeline and expands Hikma’s differentiated US portfolio to close to 130 commercialised injectable medicines including Acetaminophen injection– a more than fivefold increase over the last decade.
Lead Product(s): Paracetamol
Therapeutic Area: Neurology Product Name: Acetaminophen-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hikma Pharmaceuticals
Deal Size: $425.0 million Upfront Cash: $375.0 million
Deal Type: Acquisition September 27, 2021